Nicolás Gómez-Banoy, J Sawalla Guseh, Ge Li, Alfonso Rubio-Navarro, Tong Chen, BreAnne Poirier, Gregory Putzel, Carolina Rosselot, Maria A Pabón, João Paulo Camporez, Vijeta Bhambhani, Shih-Jen Hwang, Chen Yao, Rachel J Perry, Sushmita Mukherjee, Martin G Larson, Daniel Levy, Lukas E Dow, Gerald I Shulman, Noah Dephoure, Adolfo Garcia-Ocana, Mingming Hao, Bruce M Spiegelman, Jennifer E Ho, James C Lo
Type 2 diabetes is characterized by insulin resistance and a gradual loss of pancreatic beta cell mass and function1,2 . Currently, there are no therapies proven to prevent beta cell loss and some, namely insulin secretagogues, have been linked to accelerated beta cell failure, thereby limiting their use in type 2 diabetes3,4 . The adipokine adipsin/complement factor D controls the alternative complement pathway and generation of complement component C3a, which acts to augment beta cell insulin secretion5 ...
November 2019: Nature Medicine